Zheng Fan1, M Styner, J Muenzer, M Poe, M Escolar. 1. Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. zhengfan@med.unc.edu
Abstract
BACKGROUND AND PURPOSE: Reliable markers for predicting neurologic outcome in patients with MPS II are lacking. The purpose of this study is to explore whether quantitative volumetric measurements of brain MR imaging can be used to differentiate between MPS II patients with and without cognitive impairment. This MR imaging study is the first in MPS II patients to use automated/semi-automated methods to quantify brain volumes in a longitudinal design. MATERIALS AND METHODS: Sixteen male patients with MPS II in a natural history study had annual brain MR imaging and detailed neurodevelopmental assessment over 2 years. Automated and semi-automated methods were used to determine brain volumes. Linear mixed regression models adjusting for age were used to assess the correlation between the volumetric parameters and cognition. RESULTS: Among the 16 MPS II patients, 10 (22 MR imaging studies) had cognitive impairment whereas the other 6 (11 MR imaging studies) had normal cognition. A decreased brain tissue/ICV ratio (-5%; P < .001) and an increased lateral ventricle/ICV ratio (+4%; P = .029) were found in patients with cognitive impairment compared with patients with normal cognition. These changes were apparent in patients as young as 7 years of age in addition to older patients. CONCLUSIONS: Quantitative volumetric measurements of brain MR imaging in MPS II patients can be obtained by using automated and semi-automated segmentation methods. MPS II patients with cognitive impairment have decreased brain tissue volumes, but longer studies with more subjects are required to confirm these results.
BACKGROUND AND PURPOSE: Reliable markers for predicting neurologic outcome in patients with MPS II are lacking. The purpose of this study is to explore whether quantitative volumetric measurements of brain MR imaging can be used to differentiate between MPS IIpatients with and without cognitive impairment. This MR imaging study is the first in MPS IIpatients to use automated/semi-automated methods to quantify brain volumes in a longitudinal design. MATERIALS AND METHODS: Sixteen male patients with MPS II in a natural history study had annual brain MR imaging and detailed neurodevelopmental assessment over 2 years. Automated and semi-automated methods were used to determine brain volumes. Linear mixed regression models adjusting for age were used to assess the correlation between the volumetric parameters and cognition. RESULTS: Among the 16 MPS IIpatients, 10 (22 MR imaging studies) had cognitive impairment whereas the other 6 (11 MR imaging studies) had normal cognition. A decreased brain tissue/ICV ratio (-5%; P < .001) and an increased lateral ventricle/ICV ratio (+4%; P = .029) were found in patients with cognitive impairment compared with patients with normal cognition. These changes were apparent in patients as young as 7 years of age in addition to older patients. CONCLUSIONS: Quantitative volumetric measurements of brain MR imaging in MPS IIpatients can be obtained by using automated and semi-automated segmentation methods. MPS IIpatients with cognitive impairment have decreased brain tissue volumes, but longer studies with more subjects are required to confirm these results.
Authors: Paul A Yushkevich; Joseph Piven; Heather Cody Hazlett; Rachel Gimpel Smith; Sean Ho; James C Gee; Guido Gerig Journal: Neuroimage Date: 2006-03-20 Impact factor: 6.556
Authors: R Murata; S Nakajima; A Tanaka; N Miyagi; O Matsuoka; S Kogame; Y Inoue Journal: AJNR Am J Neuroradiol Date: 1989 Nov-Dec Impact factor: 3.825
Authors: L Vedolin; I V D Schwartz; M Komlos; A Schuch; A C Azevedo; T Vieira; F K Maeda; A M Marques da Silva; R Giugliani Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: L Vedolin; I V D Schwartz; M Komlos; A Schuch; A C Puga; L L C Pinto; A P Pires; R Giugliani Journal: AJNR Am J Neuroradiol Date: 2007 Jun-Jul Impact factor: 3.825
Authors: Manoj Kumar; Ilya M Nasrallah; Sungheon Kim; Ranjit Ittyerah; Stephen Pickup; Joel Li; Michael K Parente; John H Wolfe; Harish Poptani Journal: J Neuropathol Exp Neurol Date: 2014-01 Impact factor: 3.685
Authors: Charles H Vite; Igor Nestrasil; Anton Mlikotic; Jackie K Jens; Elizabeth M Snella; William Gross; Elsa G Shapiro; Victor Kovac; James M Provenzale; Steven Chen; Steven Q Le; Shih-hsin Kan; Shida Banakar; Raymond Y Wang; Mark E Haskins; N Matthew Ellinwood; Patricia I Dickson Journal: Comp Med Date: 2013-04 Impact factor: 0.982
Authors: Audrey A M Vollebregt; Berendine J Ebbink; Dimitris Rizopoulos; Maarten H Lequin; Femke K Aarsen; Elsa G Shapiro; Ans T van der Ploeg; Johanna M P van den Hout Journal: J Inherit Metab Dis Date: 2021-01-25 Impact factor: 4.982
Authors: Elsa G Shapiro; Kyle Rudser; Alia Ahmed; Robert D Steiner; Kathleen A Delaney; Brianna Yund; Kelly King; Alicia Kunin-Batson; Julie Eisengart; Chester B Whitley Journal: Mol Genet Metab Rep Date: 2016-04-01